Review Article

Mechanisms of Disease

THE EFFECT OF INFECTIONS ON SUSCEPTIBILITY TO AUTOIMMUNE AND ALLERGIC DISEASES

JEAN-FRANÇOIS BACH, M.D., D.SC.

INFECTIOUS agents can induce autoimmune diseases in several experimental settings, some of which have clinical counterparts. A variety of mechanisms have been invoked to explain these observations, including molecular mimicry and an increase in the immunogenicity of autoantigens caused by inflammation in the target organ.[1] Paradoxically, infectious agents can also suppress allergic and autoimmune disorders. In this review, I will summarize the evidence that the main factor in the increased prevalence of these diseases in industrialized countries is the reduction in the incidence of infectious diseases in those countries over the past three decades. This concept is not new. In 1966, for example, Leibowitz et al. suggested that the risk of multiple sclerosis is increased among persons who spent their childhood in a home with a high level of sanitation.[2] About 20 years later, Strachan observed that the risk of allergic rhinitis was inversely linked to birth order and the size of the family. He proposed that infections within households in early childhood have a role in preventing allergic rhinitis.[3] Since then, numerous epidemiologic and experimental studies have sought to clarify and extend this so-called hygiene hypothesis concerning asthma and other allergic diseases and autoimmune disorders.

CONTRASTING EPIDEMIOLOGIC TRENDS IN DEVELOPED COUNTRIES

Epidemiologic data provide strong evidence of a steady rise in the incidence of allergic and autoimmune diseases in developed countries over the past three decades. The incidence of many diseases of these two general types has increased: asthma,[4] rhinitis,[5] and atopic dermatitis,[6] representing allergic diseases, and multi-

ple sclerosis,[7,8] insulin-dependent diabetes mellitus (type 1 diabetes) — particularly in young children[9] — and Crohn's disease,[10] representing autoimmune diseases. The prevalence of asthma, hay fever, and atopic dermatitis doubled in Swedish schoolchildren between 1979 and 1991,[11] and in Lower Saxony, Germany, the incidence of multiple sclerosis also doubled from 1969 to 1986.[8] The incidence of Crohn's disease more than tripled in northern Europe from the 1950s to the 1990s.[10] The incidence of these disorders apparently began to increase in the 1950s and continues to do so today, although the incidence of some of these diseases may have plateaued.

Concomitantly, there has been an obvious decrease in the incidence of many infectious diseases in developed countries as a result of antibiotics, vaccination, or more simply, improved hygiene and better socioeconomic conditions. Figure 1 shows the estimated incidence of tuberculosis, rheumatic fever, measles, and mumps in the United States and of hepatitis A in France over a 50-year period. Intestinal infections are notable, because their frequency has decreased in developed countries as compared with less-developed countries, particularly among children. Moreover, the age at which colonization of the intestinal flora occurs differs among countries: intestinal colonization with gram-negative bacteria, for instance, occurs later in developed than in less-developed countries, both quantitatively and qualitatively.[16,17] The high prevalence of parasitic infections, notably with plasmodia and schistosoma in southern countries, contrasts with the absence of these diseases in developed countries. Furthermore, the frequency of infestation by minor parasites such as *Enterobius vermicularis* (pinworms) over the past decade has decreased in developed countries.[18,19]

THE GEOGRAPHIC DISTRIBUTION OF ALLERGIC AND AUTOIMMUNE DISEASES

The North–South Gradient

Allergic and autoimmune diseases are not evenly distributed among continents, countries, well-circumscribed regions within a given country, or ethnic groups. An examination of the distribution reveals several important and probably interrelated phenomena. One is the north–south gradient: the incidence of disease decreases from north to south in the Northern Hemisphere (and reciprocally from south to north in the Southern Hemisphere). This gradient is clearly seen in Figure 2 in the cases of multiple sclerosis and

From INSERM Unité 25, Institut de Recherches Necker–Enfants Malades, Hôpital Necker, Paris. Address reprint requests to Dr. Bach at INSERM Unité 25, Hôpital Necker, 161 rue de Sèvres, 75743 Paris CEDEX 15, France, or at bach@necker.fr.

Figure 1. Inverse Relation between the Incidence of Prototypical Infectious Diseases (Panel A) and the Incidence of Immune Disorders (Panel B) from 1950 to 2000.

In Panel A, data concerning infectious diseases are derived from reports of the Centers for Disease Control and Prevention, except for the data on hepatitis A, which are derived from Joussemet et al.[12] In Panel B, data on immune disorders are derived from Swarbrick et al.,[10] Dubois et al.,[13] Tuomilehto et al.,[14] and Pugliatti et al.[15]

type 1 diabetes in Europe. A comparison of Europe and Africa reveals a similar and even clearer trend,[22] although the epidemiologic data are less well documented in Africa. There are similar geographic differences in Europe with respect to allergy[23] and Crohn's disease[24]; in North America with respect to multiple sclerosis,[25] type 1 diabetes,[26] and Crohn's disease[27]; and in Australia with respect to multiple sclerosis.[28]

Are these differences real? Perhaps, owing to deficiencies in medical facilities, allergic and autoimmune diseases are underdiagnosed in less-developed countries. This general explanation is, however, unlikely because severe diseases like multiple sclerosis and type 1 diabetes are rarely misdiagnosed. Moreover, the differences in frequency also involve southern countries with ample medical resources, such as Greece and Spain.

Genetic Factors

There are several explanations for the gradient other than underdiagnosis. One is the role of genetic factors. For example, in Japan, there is a low frequency of HLA alleles (DR3 and DR4-DQB1*0302) that increase the likelihood of type 1 diabetes, and the incidence of the disease is also low. Conversely, the incidence of type 1 diabetes is high among residents of Sardinia (as compared with residents of neighboring regions) as well as in first-degree descendants of Sardinians who migrated to continental Italy.[29]

Environmental Factors

The contribution of genetic factors to the north–south gradient seems small, however, as compared with the contribution of environment. Environmental factors could account for the rapid increase in the incidence of allergic and autoimmune diseases in developed countries. There are striking data on the incidence of multiple sclerosis, type 1 diabetes, and asthma in populations migrating from one country to another in which the rates of these disorders differ. The rate of development of type 1 diabetes among the children of Pakistanis who migrated to the United Kingdom is the same as the rate among nonimmigrants in the United Kingdom (11.7 per 100,000), or about 10 times as high as the incidence of type 1 diabetes in Pakistan (1 per 100,000).[30,31] In Israel, multiple sclerosis is common among immigrants from Europe and rare among immigrants from Africa or Asia. By contrast, among native-born Israelis of European, African, or Asian origin, the prevalence of multiple sclerosis is as high as that among the European immigrants.[32] It is also notable that the frequency of systemic lupus erythematosus is dramatically lower in western Africans than in black Americans, two populations derived from the same ethnic group but exposed to different environments.[33] Conversely, Britons migrating to northern Australia have a decreased frequency of multiple sclerosis,[34] providing a negative control for the positive migration data, which in principle could represent underdiagnosis.

Interactions between Genetic and Environmental Factors

The degree to which genetic and environmental factors influence susceptibility to autoimmune and allergic diseases is still ill defined. The best hint derives from the concordance rates of such diseases in mono-

A   Prevalence of Multiple Sclerosis

Cases per 100,000
- ☐ <30
- ☐ 30–59
- ☐ 60–89
- ☐ ≥90

B   Incidence of Type 1 Diabetes in Children

Cases per 100,000
- ☐ 3–8
- ☐ 9–16
- ☐ 17–24
- ☐ 25–44

Figure 2. The North–South Gradient in the Prevalence of Multiple Sclerosis (Panel A) and the Incidence of Type 1 Diabetes Mellitus (Panel B) in Europe.
Adapted from Kurtzke[20] and Green and Patterson.[21]

zygotic twins. The rate is 25 percent in the case of multiple sclerosis,[35] 40 percent in the case of type 1 diabetes,[36] and 75 percent in the case of asthma.[37] One may assume that the concordance rate is directly related to penetrance of the disease, with the proviso that it is impossible to include in such analyses pairs of twins in which both twins have all the predisposing genes but are disease-free. Major progress has recently been made in identifying chromosomal areas that include genes that predispose persons to multiple sclerosis,[38] type 1 diabetes,[39] and asthma,[40] but very little information is available on the genes themselves, with the exception of HLA genes in autoimmune diseases. A crucial task is to identify which of these genes directly modulates sensitivity to inciting or protective environmental factors. An example is the observation in patients with atopic diseases of unique polymorphisms of the genes encoding interleukin-10 and transforming growth factor β (TGF-β),[41] two cytokines that might contribute to the protective effect of infections on allergic diseases.

Socioeconomic Status

An obvious factor in the north–south gradient is socioeconomic differences. Several studies have found a lower frequency of immunologic diseases in populations with a low socioeconomic status. Figure 3 shows the positive correlation between the gross national product and the incidence of asthma, type 1 diabetes, and multiple sclerosis in 12 European countries. In regions of Yorkshire[43] and Northern Ireland,[44] there is a statistically significant positive correlation between the low incidence of type 1 diabetes and certain socioeconomic indexes (unemployment, lack of a car, crowded housing conditions, and living in rental housing rather than purchased property). Similar data have been reported for Crohn's disease in the Canadian province of Manitoba.[45] Also striking is the difference in the incidence of asthma between residents of former East Germany and West Germany (the incidence is higher in the more developed West Germany), despite their common genetic background.[46]

Some infections in European countries may be distributed according to a south–north gradient that is a mirror image of the gradient for autoimmune diseases. This has been shown in the case of hepatitis A virus (HAV) infection.[47] Among Italian military recruits, atopy was less common in HAV-seropositive recruits than HAV-seronegative subjects.[48] Low socioeconomic levels and high temperatures, two common features of southern countries, may predispose inhabitants to infections in a number of ways; less stringent

Figure 3. The Frequency of Multiple Sclerosis, Type 1 Diabetes Mellitus, and Asthma in 12 European Countries According to the Gross National Product per Capita.

Adapted from Kurtzke,[20] Green and Patterson,[21] and Stewart et al.[42]

control of microbial contamination of water and food, an increased risk of bacterial proliferation with higher ambient temperatures, and poorer housing conditions may all affect the risk of contamination between persons.

Childhood Infection

When infection is an incriminating factor it often occurs early in childhood. In Yorkshire, a case–control study demonstrated a correlation between the incidence of type 1 diabetes and the degree of social mixing, including attendance at day-care centers, and the number of infections that occur before one year of age.[49] Young children with older brothers and sisters at home and those who attend a day-care center during the first six months of life subsequently have a lower incidence of asthma[50] and type 1 diabetes[49] than children who do not attend a day-care center and who have no older siblings. Children in small families tended to have a decreased incidence of atopy when they attended a day-care center in early childhood.[51]

Another influential factor is the quality of medical care, which varies substantially from country to country with respect to the use of vaccines and antibiotics. The administration of antibiotics to children has been suspected to increase the risk of asthma and allergy. Droste et al. observed that the use of antibiotics in the first year of life increased the risk of asthma or other allergic diseases in children with a genetic predisposition to atopy.[52] Antibiotics might act by decreasing the number of infectious episodes or by modifying intestinal flora. The composition of the digestive flora, indeed, differs between newborns in whom allergy develops at a later age and those in whom atopy does not develop.[53,54]

Other Factors

Other factors that may not influence the rate of infection should not necessarily be dismissed. The climate (notably the extent of exposure to sunlight) and a number of culturally based differences in behavior, notably diet, may also be important. Air pollution may have a role in asthma. But even though air pollution can worsen the clinical status of patients with asthma, it does not appear to affect the incidence of asthma. No correlation has been established between pollution indexes and the incidence of asthma.[55] German reunification provided an opportunity to study the effects of air pollution on the development of asthma and atopy. Several studies found a lower prevalence of asthma, atopic sensitization, and hay fever among residents of cities of the former East Germany, which were more polluted than West German cities.[46,56] Similarly, the prevalence of asthma in Athens, Greece, is relatively low, despite the high levels of air pollution.[57] The incidence of asthma is not lower in the countryside than in cities,[58] except in persons raised on animal farms, where one may assume that children are exposed to animal pathogens.[59]

In 1999, Braun-Fahrländer et al. tested the hypothesis that the lower prevalence of allergic diseases among persons living in rural as compared with urban environments was linked to something other than air pollution.[60] They found that children whose parents were farmers and who lived on their parents' farms were less subject to allergies than other children

from the same rural region who were not raised on a farm. A more recent study carried out in Austria, Germany, and Switzerland confirmed these findings and showed that allergies were less frequent when the children were exposed early and for a prolonged period to farm animals and cow's milk.[59] Data reported by Braun-Fahrländer et al. in this issue of the *Journal* show an inverse relation between endotoxin levels in bedding and the incidence of atopic diseases among children living in rural areas.[61] Other risk factors may include organ damage by environmental toxins and the immunomodulatory effect of vitamin D deficiency. In experiments in animals, vitamin D prevents or decreases the intensity of autoimmune diabetes and experimental allergic encephalomyelitis.[62] In humans, vitamin D deficiency may influence the risk of type 1 diabetes[63,64] and multiple sclerosis,[65] but the data are inconclusive.

IS THE DECREASED INCIDENCE OF INFECTIOUS DISEASES CAUSALLY RELATED TO THE INCREASED INCIDENCE OF IMMUNOLOGIC DISEASES?

There is anecdotal evidence that exposure to infectious diseases is associated with decreased manifestations of immune-related diseases. Measles has been reported to ameliorate the severity of the nephrotic syndrome[66] and atopic dermatitis[67,68] and transiently to suppress cutaneous delayed-hypersensitivity responses to tuberculin.[69,70] Recently, it was reported that the deliberate administration of a nonpathogenic lactobacillus to pregnant women with atopy and, ultimately, to their newborns significantly decreased the incidence of atopic dermatitis in the newborns.[71] Similarly, the administration of probiotics (which are live, nonpathogenic microbes incorporated into food) to infants with atopic dermatitis improved the skin lesions.[72] Children who received antibiotics during infancy had a higher incidence of allergy and other atopic disorders than children who had not received antibiotics[52,73] — a finding in keeping with the observation that oral kanamycin enhances the production of cytokines that promote allergic reactions in infant mice.[74] In addition, regular anthelmintic treatment of children in a slum area of Caracas, Venezuela, where helminths are endemic, was associated with an increased incidence of immediate hypersensitivity to environmental allergens (on the basis of skin tests and specific IgE antibody tests).[75]

Animal Models

The best evidence of a causal relation between infections and allergic or autoimmune diseases derives from animal models. It has been consistently observed that autoimmune diseases in susceptible strains of mice or rats develop earlier and at a higher rate among an-

imals bred in a specific pathogen-free environment than among animals bred in a conventional environment. In nonobese diabetic (NOD) mice and in BB rats, the use of cesarean delivery and isolated living conditions increases the incidence of diabetes from 40 percent to 80 percent[76] (and Chatenoud L: personal communication) (Fig. 4). A similar effect of the use of specific pathogen-free conditions has been reported in rats with collagen-induced arthritis[77] or adjuvant arthritis[78]; the effect was abrogated in the latter case by treatment with neomycin.

Diabetes is prevented in NOD mice by infecting the young mice with mycobacteria,[79] lymphocytic choriomeningitis virus,[80] murine hepatitis virus,[81] lactate dehydrogenase virus,[82] or schistosoma[83] and filariae.[84] Infection of lupus-prone NZB mice or (NZB×NZW)F1 hybrid mice with lactate dehydrogenase virus or *Plasmodium berghei* prevents lupus.[85,86] Treatment with killed bacteria (complete Freund's adjuvant)[87] or bacterial extracts (streptococci[88] or klebsiellae[89]) offers a similar degree of protection against diabetes in NOD mice. Treatment with mycobacteria also protects against experimental allergic encephalomyelitis[90,91] and inhibits the production of IgE antibodies, and the administration of *Mycobacterium bovis* and *M. vaccae* can attenuate the late-phase response, airway hyperresponsiveness, and eosinophilia in bronchoalveolar-lavage fluid in a mouse model of bronchial asthma.[92]

UNDERLYING MECHANISMS

Type 1 and Type 2 Helper T Cells

How infections protect against allergic and autoimmune diseases is unknown. The development of most autoimmune diseases depends on the cytokines interleukin-2 and interferon-γ produced by type 1 helper T cells (Th1), whereas the development of allergic diseases requires interleukin-4 and interleukin-5, both of which are produced by type 2 helper T cells (Th2). The reciprocal down-regulation of Th1 cells by Th2 cytokines and of Th2 cells by Th1 cytokines raises the possibility that these cytokines are involved in the infection-mediated protection against allergy or autoimmunity. Contrary to initial reports,[93] there is a trend toward an association between allergic and autoimmune diseases in individual patients: the frequency of atopic diseases is increased in patients with diabetes and rheumatoid arthritis.[94,95] These observations would fit with the concept of common mechanisms underlying infection-mediated protection against autoimmunity and allergy.

Regulatory T Cells and Cytokines

In NOD mice and in rats with experimental allergic encephalomyelitis — a demyelinating autoimmune disease — the protection against these conditions afforded by treatment with mycobacteria can be trans-

Conventional Breeding Conditions

Breeding in a Specific Pathogen-free Environment

Figure 4. Effect of Infections on the Incidence of Diabetes in Female Nonobese Diabetic Mice.

The incidence of diabetes, which is normally stable in successive generations bred in a conventional environment (generation 1 and generation 2), increases immediately after breeding conditions are changed to a specific pathogen-free environment through the use of cesarean delivery and isolated living conditions (generation 3 and generation 4).

ferred to uninfected animals by CD4+ T cells,[96] and protection is abrogated by treatment with cyclophosphamide, a drug that may act selectively on regulatory T cells.[91,96] In NOD mice, the protection against diabetes afforded by the administration of killed mycobacteria may involve the production of Th2 cytokines within the islets,[97] and such protection can be nullified by treatment with antibodies against interleukin-4 and interleukin-10.[98] However, since mycobacteria protect NOD mice from diabetes even if the animals lack functional interleukin-4 and interleukin-10 genes,[99] other mechanisms may be responsible for this effect. Considerable attention has been focused on CD4+ T cells that express the α chain of the interleukin-2 receptor (CD25), since the depletion of these cells in nonautoimmune mice induces a polyautoimmune syndrome.[100] The mechanism of action of these CD25+ regulatory T cells is still ill defined but may involve transforming growth factor β (TGF-β)[101]; it is not clear whether infections activate these cells. Natural killer T cells, which have properties of both natural killer cells and T cells, may also contribute importantly to immunoregulation.[102]

Interleukin-10, which is produced by Th2 cells, monocytes, and macrophages, slows the progression of autoimmune and allergic diseases in experimental models.[103] Production of interleukin-10 is increased in a number of infectious diseases, and this cytokine probably helps suppress the immunopathologic complications of such infections.[103] For example, the unresponsiveness of T cells in in vitro models of lepromatous leprosy can be reversed by the addition of neutralizing antibody against interleukin-10.[104] Interleukin-10 may also play a part in allergic diseases by

shortening the survival of activated (lipopolysaccharide-stimulated) eosinophils.[105] Two groups of investigators have found that there is considerably less interleukin-10 in the lungs of patients with asthma than in the lungs of control subjects,[106,107] although there is a contradictory report.[108] Conversely, schistosoma infection in Gabonese children is associated with increased serum levels of interleukin-10 and a decreased incidence of immediate hypersensitivity to house-dust mite antigens,[109] and the oral administration of lactobacillus, which protects against atopy, stimulates the production of interleukin-10.[110] In any case, interleukin-10 is not the only factor since, as already mentioned, the administration of killed mycobacteria protects against diabetes in NOD mice in which the interleukin-10 gene has been knocked out.[99]

Taken together, the data suggest that infectious agents stimulate the production of regulatory cells whose effects extend beyond the responses to the invading microbe (bystander suppression).[111,112] Interleukin-10 and TGF-β, which may be produced by CD25+ and other regulatory T cells,[113] can inhibit both Th1 and Th2 responses and are plausible candidates as mediators of this regulation. It is of interest in this context that *M. vaccae*–induced protection against allergic bronchial inflammation is mediated by allergen-specific CD4+ CD45 RB[low] T cells and inhibited by neutralizing antibodies against interleukin-10 and TGF-β.[114]

Other Mechanisms

A second mechanism with relevance to the influence of infection on allergy and autoimmunity is antigenic competition, in which the immune response

to an antigen is decreased by a concomitant immune response against an unrelated antigen.[115,116] The competition is maximal when the unrelated antigen is administered a few days after the administration of the first antigen. Antigenic competition can affect both antibody production (including that of IgE) and cell-mediated immune responses as well as autoimmune and allergic responses.[115,116] The mechanisms of antigenic competition remain unknown despite numerous investigations.[117,118]

The transfer of maternal antiviral antibodies to newborns may also have a role in the susceptibility to autoimmune diseases. Zinkernagel suggested that decreased exposure of women to particular viruses before pregnancy may subsequently reduce the degree of protection against these viruses afforded to their newborns.[119] Exposure to these viruses could provoke an immune response in the children that could ultimately lead to an autoimmune disease. This hypothesis could apply to the development of type 1 diabetes, in which rubella virus and coxsackie B virus have been implicated.

Another mechanism by which bacteria and viruses could protect against immune disorders is related to Toll-like receptors (TLRs), which are receptors for various bacterial components. TLR2 serves as a receptor for peptidoglycan and bacterial lipoproteins, TLR4 as a receptor for gram-negative lipopolysaccharide, TLR5 as a receptor for flagellin, and TLR9 as a receptor for the CpG motif of bacterial DNA.[120] When they bind these bacterial ligands, TLRs stimulate mononuclear cells to produce cytokines, some of which could down-regulate allergic and autoimmune responses. A TLR-mediated effect probably explains the protective effect of the CpG motif against diabetes in NOD mice.[121] Investigation of the role of TLRs in human allergic and autoimmune diseases is just beginning.

There are other mechanisms through which infectious agents may have immunosuppressive properties that are not related to the immune response to specific antigens. Superantigens, which are components of some bacterial products or of viral proteins, may induce the deletion or, sometimes, the activation of T cells expressing a given T-cell receptor *V* gene. The possible role of superantigens in protection against immune disease is illustrated by the fact that experimental allergic encephalomyelitis is prevented by treatment with staphylococcal enterotoxin B.[122] Staphylococcal enterotoxin B has also been shown to inhibit the development of lupus nephritis in MRL/1pr mice.[123]

Recent studies have indicated that measles-induced immunosuppression could be mediated by the direct effect of two measles virus proteins on mononuclear cells.[124] A large variety of parasitic infections are associated with generalized immunosuppression, an ef-

fect that is apparently not directly related to the antiparasitic immune response.[125-127]

CLINICAL IMPLICATIONS

The relation between the reduction in the incidence of infectious diseases and the increase in the incidence of allergic and autoimmune diseases, on the one hand, and the apparent protective effect of infections against immune-mediated diseases, on the other hand, have clear clinical implications. A major problem with these correlations is that the infections contributing to protection or susceptibility are ill defined. Moreover, certain infectious agents can trigger allergic or autoimmune diseases. Two lines of research are needed: one should focus on strengthening the epidemiologic evidence, especially through the use of prospective studies. Some allergic and autoimmune diseases are amenable to prospective epidemiologic investigations because they occur early in life (such as atopic dermatitis, asthma, and type 1 diabetes), thereby reducing the survey time. The second line of research should attempt to reduce the incidence of selected allergic and autoimmune diseases by innocuous immunostimulation. Positive results involving treatment with a mycobacterial extract[128] and probiotics[71,72] have recently been reported in patients with atopic dermatitis. Vaccination with bacille Calmette–Guérin produced negative results in patients with type 1 diabetes, possibly because the duration of treatment was too short.[129,130] This approach has produced encouraging results in patients with multiple sclerosis,[131] and it should be investigated further once the treatment is found to be safe.

Vaccination strategies should be examined in the context of the hygiene hypothesis, notably in relation to vaccination with bacille Calmette–Guérin. The problem is complex. Vaccinations may cause immunostimulation and thus have a favorable effect, or they may prevent "protective" infections and thus have an unfavorable effect. It is important to stress that there are no solid data indicating either a positive or a negative role of vaccinations in the development of autoimmune or allergic diseases. The potential benefit of antibiotic therapy in situations in which the pathogenic role of a bacterium is doubtful should be carefully assessed. In addition to the problem of antibiotic resistance, unnecessary treatment with antibiotics could reduce the degree of physiological immunostimulation afforded by commensal bacteria.

There is a certain irony in the fact that we must now search for new ways to reproduce the infectious diseases against which we have been fighting with great success over the past three decades. The challenge is an important one because of the high morbidity of allergic and autoimmune diseases. In fact, it might extend to other immune disorders, notably non-Hodg-

kin's lymphomas, the frequency of which is also increasing in developed countries.[132,133]

REFERENCES

1. Olson JK, Croxford JL, Miller SD. Virus-induced autoimmunity: potential role of viruses in initiation, perpetuation, and progression of T-cell-mediated autoimmune disease. Viral Immunol 2001;14:227-50.
2. Leibowitz U, Antonovsky A, Medalie JM, Smith HA, Halpern L, Alter M. Epidemiological study of multiple sclerosis in Israel. II. Multiple sclerosis and level of sanitation. J Neurol Neurosurg Psychiatry 1966;29:60-8.
3. Strachan DP. Hay fever, hygiene, and household size. BMJ 1989;299:1259-60.
4. Woolcock AJ, Peat JK. Evidence for the increase in asthma worldwide. CIBA Found Symp 1997;206:122-34.
5. Upton MN, McConnachie A, McSharry C, et al. Intergenerational 20 year trends in the prevalence of asthma and hay fever in adults: the Midspan family study surveys of parents and offspring. BMJ 2000;321:88-92.
6. Williams HC. Is the prevalence of atopic dermatitis increasing? Clin Exp Dermatol 1992;17:385-91.
7. Rosati G, Aiello I, Mannu L, et al. Incidence of multiple sclerosis in the town of Sassari, Sardinia, 1965 to 1985: evidence for increasing occurrence of the disease. Neurology 1988;38:384-8.
8. Poser S, Stickel B, Krtsch U, Burckhardt D, Nordman B. Increasing incidence of multiple sclerosis in South Lower Saxony, Germany. Neuroepidemiology 1989;8:207-13.
9. EURODIAB ACE Study Group. Variation and trends in incidence of childhood diabetes in Europe. Lancet 2000;355:873-6. [Erratum, Lancet 2000;356:1690.]
10. Swarbrick ET, Farrokhyar F, Irvine EJ. A critical review of epidemiological studies in inflammatory bowel disease. Scand J Gastroenterol 2001;36:2-15. [Erratum, Scand J Gastroenterol 2001;36:560a.]
11. Aberg N, Hesselmar B, Aberg B, Eriksson B. Increase of asthma, allergic rhinitis and eczema in Swedish schoolchildren between 1979 and 1991. Clin Exp Allergy 1995;25:815-9.
12. Joussemet M, Depaquit J, Nicand E, et al. Effondrement de la séroprévalence de l'hepatite virale A chez les jeunes français. Gastroenterol Clin Biol 1999;23:447.
13. Dubois P, Degrave E, Vandenplas O. Asthma and airway hyperresponsiveness among Belgian conscripts, 1978-91. Thorax 1998;53:101-5.
14. Tuomilehto J, Karvonen M, Pitkaniemi J, et al. Record-high incidence of type I (insulin-dependent) diabetes mellitus in Finnish children. Diabetologia 1999;42:655-60.
15. Pugliatti M, Sotgiu S, Solinas G, et al. Multiple sclerosis epidemiology in Sardinia: evidence for a true increasing risk. Acta Neurol Scand 2001;103:20-6.
16. Adlerberth I, Carlsson B, de Man P, et al. Intestinal colonization with Enterobacteriaceae in Pakistani and Swedish hospital-delivered infants. Acta Paediatr Scand 1991;80:602-10.
17. Adlerberth I, Jalil F, Carlsson B, et al. High turnover rate of Escherichia coli strains in the intestinal flora of infants in Pakistan. Epidemiol Infect 1998;121:587-98.
18. Gale EAM. A missing link in the hygiene hypothesis? Diabetologia 2002;45:588-94.
19. Vermund SH, MacLeod S. Is pinworm a vanishing infection? Laboratory surveillance in a New York City medical center from 1971 to 1986. Am J Dis Child 1988;142:566-8.
20. Kurtzke JF. Multiple sclerosis in time and space — geographic clues to cause. J Neurovirol 2000;6:Suppl 2:S134-S140.
21. Green A, Patterson CC. Trends in the incidence of childhood-onset diabetes in Europe 1989-1998. Diabetologia 2001;44:Suppl 3:B3-B8.
22. Weinberg EG. Urbanization and childhood asthma: an African perspective. J Allergy Clin Immunol 2000;105:224-31.
23. The International Study of Asthma and Allergies in Childhood (ISAAC) Steering Committee. Worldwide variation in prevalence of symptoms of asthma, allergic rhinoconjunctivitis, and atopic eczema: ISAAC. Lancet 1998;351:1225-32.
24. Shivananda S, Lennard-Jones J, Logan R, et al. Incidence of inflammatory bowel disease across Europe: is there a difference between north and south? Results of the European Collaborative Study on Inflammatory Bowel Disease (EC-IBD). Gut 1996;39:690-7.
25. Hernan MA, Olek MJ, Ascherio A. Geographic variation of MS incidence in two prospective studies of US women. Neurology 1999;53:1711-8.
26. Diabetes Epidemiology Research International Group. Geographic patterns of childhood insulin-dependent diabetes mellitus. Diabetes 1988;37:1113-9.
27. Sonnenberg A, McCarty DJ, Jacobsen SJ. Geographic variation of inflammatory bowel disease within the United States. Gastroenterology 1991;100:143-9.
28. McLeod JG, Hammond SR, Hallpike JF. Epidemiology of multiple sclerosis in Australia: with NSW and SA survey results. Med J Aust 1994;160:117-22.
29. Muntoni S, Fonte MT, Stoduto S, et al. Incidence of insulin-dependent diabetes mellitus among Sardinian-heritage children born in Lazio region, Italy. Lancet 1997;349:160-2.
30. Bodansky HJ, Staines A, Stephenson C, Haigh D, Cartwright R. Evidence for an environmental effect in the aetiology of insulin dependent diabetes in a transmigratory population. BMJ 1992;304:1020-2.
31. Staines A, Hanif S, Ahmed S, McKinney PA, Shera S, Bodansky HJ. Incidence of insulin dependent diabetes mellitus in Karachi, Pakistan. Arch Dis Child 1997;76:121-3.
32. Leibowitz U, Kahana E, Alter M. The changing frequency of multiple sclerosis in Israel. Arch Neurol 1973;29:107-10.
33. Symmons DPM. Frequency of lupus in people of African origin. Lupus 1995;4:176-8.
34. Hammond SR, English DR, McLeod JG. The age-range of risk of developing multiple sclerosis: evidence from a migrant population in Australia. Brain 2000;123:968-74.
35. Mumford CJ, Wood NW, Kellar-Wood H, Thorpe JW, Miller DH, Compston DA. The British Isles survey of multiple sclerosis in twins. Neurology 1994;44:11-5.
36. Bach JF. Insulin-dependent diabetes mellitus as an autoimmune disease. Endocr Rev 1994;15:516-42.
37. Skadhauge LR, Christensen K, Kyvik KO, Sigsgaard T. Genetic and environmental influence on asthma: a population-based study of 11,688 Danish twin pairs. Eur Respir J 1999;13:8-14.
38. Oksenberg JR, Baranzini SE, Barcellos LF, Hauser SL. Multiple sclerosis: genomic rewards. J Neuroimmunol 2001;113:171-84.
39. Todd JA. Genetics of type 1 diabetes. Pathol Biol (Paris) 1997;45:219-27.
40. Cookson WOC. Asthma genetics. Chest 2002;121:Suppl:7S-13S.
41. Hobbs K, Negri J, Klinnert M, Rosenwasser LJ, Borish L. Interleukin-10 and transforming growth factor-beta promoter polymorphisms in allergies and asthma. Am J Respir Crit Care Med 1998;158:1958-62.
42. Stewart AW, Mitchell EA, Pearce N, Strachan DP, Weilandon SK. The relationship of per capita gross national product to the prevalence of symptoms of asthma and other atopic diseases in children (ISAAC). Int J Epidemiol 2001;30:173-9.
43. Staines A, Bodansky HJ, McKinney PA, et al. Small area variation in the incidence of childhood insulin-dependent diabetes mellitus in Yorkshire, UK: links with overcrowding and population density. Int J Epidemiol 1997;26:1307-13.
44. Patterson CC, Carson DJ, Hadden DR. Epidemiology of childhood IDDM in Northern Ireland 1989-1994: low incidence in areas with highest population density and most household crowding. Diabetologia 1996;39:1063-9.
45. Blanchard JF, Bernstein CN, Wajda A, Rawsthorne P. Small-area variations and sociodemographic correlates for the incidence of Crohn's disease and ulcerative colitis. Am J Epidemiol 2001;154:328-35.
46. Von Mutius E, Martinez FD, Fritzsch C, Nicolai T, Roell G, Thiemann HH. Prevalence of asthma and atopy in two areas of West and East Germany. Am J Respir Crit Care Med 1994;149:358-64.
47. Bach JF. Predictive medicine in autoimmune diseases: from the identification of genetic predisposition and environmental influence to precocious immunotherapy. Clin Immunol Immunopathol 1994;72:156-61.
48. Matricardi PM, Rosmini F, Ferrigno L, et al. Cross sectional retrospective study of prevalence of atopy among Italian military students with antibodies against hepatitis A virus. BMJ 1997;314:999-1003.
49. McKinney PA, Okasha M, Parslow RC, et al. Early social mixing and childhood type 1 diabetes mellitus: a case-control study in Yorkshire, UK. Diabet Med 2000;17:236-42.
50. Ball TM, Castro-Rodriguez JA, Griffith KA, Holberg CJ, Martinez FD, Wright AL. Siblings, day-care attendance, and the risk of asthma and wheezing during childhood. N Engl J Med 2000;343:538-43.
51. Kramer U, Heinrich J, Wjst M, Wichmann HE. Age of entry to day nursery and allergy in later childhood. Lancet 1999;353:450-4.

52. Droste JHJ, Wieringa MH, Weyler JJ, Nelen VJ, Vermeire PA, Van Bever HP. Does the use of antibiotics in early childhood increase the risk of asthma and allergic disease? Clin Exp Allergy 2000;30:1547-53.

53. Bjorksten B, Sepp E, Julge K, Voor T, Mikelsaar M. Allergy development and the intestinal microflora during the first year of life. J Allergy Clin Immunol 2001;108:516-20.

54. Kalliomaki M, Kirjavainen P, Eerola E, Kero P, Salminen S, Isolauri E. Distinct patterns of neonatal gut microflora in infants in whom atopy was and was not developing. J Allergy Clin Immunol 2001;107:129-34.

55. Anderson HR. Air pollution and trends in asthma. CIBA Found Symp 1997;206:190-202.

56. Nowak D, Heinrich J, Jorres R, et al. Prevalence of respiratory symptoms, bronchial hyperresponsiveness and atopy among adults: West and East Germany. Eur Respir J 1996;9:2541-52.

57. Papageorgiou N, Gaga M, Marossis C, et al. Prevalence of asthma and asthma-like symptoms in Athens, Greece. Respir Med 1997;91:83-8.

58. Charpin D, Kleisbauer JP, Lanteaume A, Vervloet D, Lagier F, Charpin J. Existe-t-il un facteur urbain dans l'asthme et l'allergie? Rev Mal Respir 1988;5:109-14.

59. Riedler J, Braun-Fahrlander C, Eder W, et al. Exposure to farming in early life and development of asthma and allergy: a cross-sectional survey. Lancet 2001;358:1129-33.

60. Braun-Fahrländer C, Gassner M, Grize L, et al. Prevalence of hay fever and allergic sensitization in farmer's children and their peers living in the same rural community. Clin Exp Allergy 1999;29:28-34.

61. Braun-Fahrländer C, Riedler J, Herz U, et al. Environmental exposure to endotoxin and its relation to asthma in school-age children. N Engl J Med 2002;347:869-77.

62. Mathieu C, Adorini L. The coming of age of 1,25-dihydroxyvitamin D(3) analogs as immunomodulatory agents. Trends Mol Med 2002;8:174-9.

63. The EURODIAB Substudy 2 Study Group. Vitamin D supplement in early childhood and risk for type I (insulin-dependent) diabetes mellitus. Diabetologia 1999;42:51-4.

64. Hypponen E, Laara E, Reunanen A, Jarvelin MR, Virtanen SM. Intake of vitamin D and risk of type 1 diabetes: a birth-cohort study. Lancet 2001;358:1500-3.

65. Hayes CE, Cantorna MT, DeLuca HF. Vitamin D and multiple sclerosis. Proc Soc Exp Biol Med 1997;216:21-7.

66. Blumberg RW, Cassady HA. Effect of measles on the nephrotic syndrome. Am J Dis Child 1947;73:151-66.

67. Kondo N, Fukutomi O, Ozawa T, et al. Improvement of food-sensitive atopic dermatitis accompanied by reduced lymphocyte responses to food antigen following natural measles virus infection. Clin Exp Allergy 1993;23:44-50.

68. Boner AL, Valletta EA, Bellanti JA. Improvement of atopic dermatitis following natural measles virus infection: four case reports. Ann Allergy 1985;55:605-8.

69. Pirquet C. Das Verhalten der kutanen Tuberkulinreaktion während der Masern. Deutsche Med Wochenschr 1908;34:1297-300.

70. Tamashiro VG, Perez HH, Griffin DE. Prospective study of the magnitude and duration of changes in tuberculin reactivity during uncomplicated and complicated measles. Pediatr Infect Dis J 1987;6:451-4.

71. Kalliomaki M, Salminen S, Arvilommi H, Kero P, Koskinen P, Isolauri E. Probiotics in primary prevention of atopic disease: a randomised placebo-controlled trial. Lancet 2001;357:1076-9.

72. Isolauri E, Arvola T, Sutas Y, Moilanen E, Salminen S. Probiotics in the management of atopic eczema. Clin Exp Allergy 2000;30:1604-10.

73. Wickens K, Pearce N, Crane J, Beasley R. Antibiotic use in early childhood and the development of asthma. Clin Exp Allergy 1999;29:766-71.

74. Oyama N, Sudo N, Sogawa H, Kubo C. Antibiotic use during infancy promotes a shift in the T(H)1/T(H)2 balance toward TH2-dominant immunity in mice. J Allergy Clin Immunol 2001;107:153-9.

75. Lynch NR, Hagel I, Perez M, Di Prisco MC, Lopez R, Alvarez N. Effect of anthelmintic treatment on the allergic reactivity of children in a tropical slum. J Allergy Clin Immunol 1993;92:404-11.

76. Like AA, Guberski DL, Butler L. Influence of environmental viral agents on frequency and tempo of diabetes mellitus in BB/Wor rats. Diabetes 1991;40:259-62.

77. Breban MA, Moreau MC, Fournier C, Ducluzeau R, Kahn MF. Influence of the bacterial flora on collagen-induced arthritis in susceptible and resistant strains of rats. Clin Exp Rheumatol 1993;11:61-4.

78. Moudgil KD, Kim E, Yun OJ, Chi HH, Brahn E, Sercarz EE. Environmental modulation of autoimmune arthritis involves the spontaneous microbial induction of T cell responses to regulatory determinants within heat shock protein 65. J Immunol 2001;166:4237-43. [Erratum, J Immunol 2001;166:6992.]

79. Martins TC, Aguas AP. Mechanisms of Mycobacterium avium-induced resistance against insulin-dependent diabetes mellitus (IDDM) in non-obese diabetic (NOD) mice: role of Fas and Th1 cells. Clin Exp Immunol 1999;115:248-54.

80. Oldstone MB, Ahmed R, Salvato M. Viruses as therapeutic agents. II. Viral reassortants map prevention of insulin-dependent diabetes mellitus to the small RNA of lymphocytic choriomeningitis virus. J Exp Med 1990;171:2091-100.

81. Wilberz S, Partke HJ, Dagnaes-Hansen F, Herberg L. Persistent MHV (mouse hepatitis virus) infection reduces the incidence of diabetes mellitus in non-obese diabetic mice. Diabetologia 1991;34:2-5.

82. Takei I, Asaba Y, Kasatani T, et al. Suppression of development of diabetes in NOD mice by lactate dehydrogenase virus infection. J Autoimmun 1992;5:665-73.

83. Cooke A, Tonks P, Jones FM, et al. Infection with Schistosoma mansoni prevents insulin dependent diabetes mellitus in non-obese diabetic mice. Parasite Immunol 1999;21:169-76.

84. Imai S, Tezuka H, Fujita K. A factor of inducing IgE from a filarial parasite prevents insulin-dependent diabetes mellitus in nonobese diabetic mice. Biochem Biophys Res Commun 2001;286:1051-8.

85. Greenwood BM, Herrick EM, Voller A. Suppression of autoimmune disease in NZB and (NZB x NZW) F1 hybrid mice by infection with malaria. Nature 1970;226:266-7.

86. Oldstone MB, Dixon FJ. Inhibition of antibodies to nuclear antigen and to DNA in New Zealand mice infected with lactate dehydrogenase virus. Science 1972;175:784-6.

87. Sadelain MW, Qin HY, Lauzon J, Singh B. Prevention of type I diabetes in NOD mice by adjuvant immunotherapy. Diabetes 1990;39:583-9.

88. Toyota T, Satoh J, Oya K, Shintani S, Okano T. Streptococcal preparation (OK-432) inhibits development of type I diabetes in NOD mice. Diabetes 1986;35:496-9.

89. Sai P, Rivereau AS. Prevention of diabetes in the nonobese diabetic mouse by oral immunological treatments: comparative efficiency of human insulin and two bacterial antigens, lipopolysaccharide from Escherichia coli and glycoprotein extract from Klebsiella pneumoniae. Diabetes Metab 1996;22:341-8.

90. Lehmann D, Ben-Nun A. Bacterial agents protect against autoimmune disease. I. Mice pre-exposed to Bordetella pertussis or Mycobacterium tuberculosis are highly refractory to induction of experimental autoimmune encephalomyelitis. J Autoimmun 1992;5:675-90.

91. Hempel K, Freitag A, Freitag B, Endres B, Mai B, Liebaldt G. Unresponsiveness to experimental allergic encephalomyelitis in Lewis rats pretreated with complete Freund's adjuvant. Int Arch Allergy Appl Immunol 1985;76:193-9.

92. Hopfenspirger MT, Parr SK, Hopp RJ, Townley RG, Agrawal DK. Mycobacterial antigens attenuate late phase response, airway hyperresponsiveness, and bronchoalveolar lavage eosinophilia in a mouse model of bronchial asthma. Int Immunopharmacol 2001;1:1743-51.

93. The EURODIAB Substudy 2 Study Group. Decreased prevalence of atopic diseases in children with diabetes. J Pediatr 2000;137:470-4.

94. Kero J, Gissler M, Hemminki E, Isolauri E. Could TH1 and TH2 diseases coexist? Evaluation of asthma incidence in children with coeliac disease, type 1 diabetes, or rheumatoid arthritis: a register study. J Allergy Clin Immunol 2001;108:781-3.

95. Simpson CR, Anderson WJA, Helms PJ, et al. Coincidence of immune-mediated diseases driven by Th1 and Th2 subsets suggests a common aetiology: a population-based study using computerized general practice data. Clin Exp Allergy 2002;32:37-42.

96. Qin HY, Sadelain MW, Hitchon C, Lauzon J, Singh B. Complete Freund's adjuvant-induced T cells prevent the development and adoptive transfer of diabetes in nonobese diabetic mice. J Immunol 1993;150:2072-80.

97. Shehadeh NN, LaRosa F, Lafferty KJ. Altered cytokine activity in adjuvant inhibition of autoimmune diabetes. J Autoimmun 1993;6:291-300.

98. Calcinaro F, Gambelunghe G, Lafferty KJ. Protection from autoimmune diabetes by adjuvant therapy in the non-obese diabetic mouse: the role of interleukin-4 and interleukin-10. Immunol Cell Biol 1997;75:467-71.

99. Serreze DV, Chapman HD, Post CM, Johnson EA, Suarez-Pinzon WL, Rabinovitch A. Th1 to Th2 cytokine shifts in nonobese diabetic mice: sometimes an outcome, rather than the cause, of diabetes resistance elicited by immunostimulation. J Immunol 2001;166:1352-9.

100. Asano M, Toda M, Sakaguchi N, Sakaguchi S. Autoimmune disease as a consequence of developmental abnormality of a T cell subpopulation. J Exp Med 1996;184:387-96.

101. Nakamura K, Kitani A, Strober W. Cell contact-dependent immunosuppression by CD4(+)CD25(+) regulatory T cells is mediated by cell surface-bound transforming growth factor beta. J Exp Med 2001;194:629-44.

102. Bendelac A, Rivera MN, Park SH, Roark JH. Mouse CD1-specific NK1 T cells: development, specificity, and function. Annu Rev Immunol 1997;15:535-62.

103. Moore KW, de Waal Malefyt R, Coffman RL, O'Garra A. Interleukin-10 and the interleukin-10 receptor. Annu Rev Immunol 2001;19:683-765.

104. Sieling PA, Abrams JS, Yamamura M, et al. Immunosuppressive roles for IL-10 and IL-4 in human infection: in vitro modulation of T cell responses in leprosy. J Immunol 1993;150:5501-10.

105. Takanashi S, Nonaka R, Xing Z, O'Byrne P, Dolovich J, Jordana M. Interleukin 10 inhibits lipopolysaccharide-induced survival and cytokine production by human peripheral blood eosinophils. J Exp Med 1994;180:711-5.

106. Lim S, Crawley E, Woo P, Barnes PJ. Haplotype associated with low interleukin-10 production in patients with severe asthma. Lancet 1998;352:113.

107. Takanashi S, Hasegawa Y, Kanehira Y, et al. Interleukin-10 level in sputum is reduced in bronchial asthma, COPD and in smokers. Eur Respir J 1999;14:309-14.

108. Robinson DS, Tsicopoulos A, Meng Q, Durham S, Kay AB, Hamid Q. Increased interleukin-10 messenger RNA expression in atopic allergy and asthma. Am J Respir Cell Mol Biol 1996;14:113-7.

109. van den Biggelaar AHJ, van Ree R, Rodrigues LC, et al. Decreased atopy in children infected with Schistosoma haematobium: a role for parasite-induced interleukin-10. Lancet 2000;356:1723-7.

110. Pessi T, Sutas Y, Hurme H, Isolauri E. Interleukin-10 generation in atopic children following oral Lactobacillus rhamnosus GG. Clin Exp Allergy 2000;30:1804-8.

111. al-Sabbagh A, Miller A, Santos LM, Weiner HL. Antigen-driven tissue-specific suppression following oral tolerance: orally administered myelin basic protein suppresses proteolipid protein-induced experimental autoimmune encephalomyelitis in the SJL mouse. Eur J Immunol 1994;24:2104-9.

112. Weiner HL, Friedman A, Miller A, et al. Oral tolerance: immunologic mechanisms and treatment of animal and human organ-specific autoimmune diseases by oral administration of autoantigens. Annu Rev Immunol 1994;12:809-37.

113. Groux H, O'Garra A, Bigler M, et al. A CD4+ T-cell subset inhibits antigen-specific T-cell responses and prevents colitis. Nature 1997;389:737-42.

114. Zuany-Amorim C, Sawicka E, Manlius C, et al. Suppression of airway eosinophilia by killed Mycobacterium vaccae-induced allergen-specific regulatory T-cells. Nat Med 2002;8:625-9.

115. Liacopoulos P, Ben-Efraim S. Antigenic competition. Prog Allergy 1975;18:97-204.

116. Pross HF, Eidinger D. Antigenic competition: a review of nonspecific antigen-induced suppression. Adv Immunol 1974;18:133-68.

117. Buus S, Sette A, Colon SM, Miles C, Grey HM. The relation between major histocompatibility complex (MHC) restriction and the capacity of Ia to bind immunogenic peptides. Science 1987;235:1353-8.

118. Guillet JG, Lai MZ, Briner TJ, et al. Immunological self, nonself discrimination. Science 1987;235:865-70.

119. Zinkernagel RM. Maternal antibodies, childhood infections, and autoimmune diseases. N Engl J Med 2001;345:1331-5.

120. Akira S, Takeda K, Kaisho T. Toll-like receptors: critical proteins linking innate and acquired immunity. Nat Immunol 2001;2:675-80.

121. Quintana FJ, Rotem A, Carmi P, Cohen IR. Vaccination with empty plasmid DNA or CpG oligonucleotide inhibits diabetes in nonobese diabetic mice: modulation of spontaneous 60-kDa heat shock protein autoimmunity. J Immunol 2000;165:6148-55.

122. Soos JM, Schiffenbauer J, Johnson HM. Treatment of PL/J mice with the superantigen, staphylococcal enterotoxin B, prevents development of experimental allergic encephalomyelitis. J Neuroimmunol 1993;43:39-43.

123. Kim C, Siminovitch KA, Ochi A. Reduction of lupus nephritis in MRL/lpr mice by a bacterial superantigen treatment. J Exp Med 1991;174:1431-7.

124. Marie JC, Kehren J, Trescol-Biemont MC, et al. Mechanism of measles virus-induced suppression of inflammatory immune responses. Immunity 2001;14:69-79.

125. Scorza T, Magez S, Brys L, de Baetselier P. Hemozoin is a key factor in the induction of malaria-associated immunosuppression. Parasite Immunol 1999;21:545-54.

126. Ouaissi A, Guevara-Espinoza A, Chabe F, Gomez-Corvera R, Taibi A. A novel and basic mechanism of immunosuppression in Chagas' disease: Trypanosoma cruzi releases in vitro and in vivo a protein which induces T cell unresponsiveness through specific interaction with cysteine and glutathione. Immunol Lett 1995;48:221-4.

127. Mazingue C, Stadler BM, Quatannens B, Capron A, de Weck A. Schistosome-derived inhibitory factor: an immunosuppressive agent preferentially active on T lymphocytes. Int Arch Allergy Appl Immunol 1986;80:347-54.

128. Arkwright PD, David TJ. Intradermal administration of a killed Mycobacterium vaccae suspension (SRL 172) is associated with improvement in atopic dermatitis in children with moderate-to-severe disease. J Allergy Clin Immunol 2001;107:531-4.

129. Allen HF, Klingensmith GJ, Jensen P, Simoes E, Hayward A, Chase HP. Effect of Bacillus Calmette-Guerin vaccination on new-onset type 1 diabetes: a randomized clinical study. Diabetes Care 1999;22:1703-7.

130. Elliott JF, Marlin KL, Couch RM. Effect of bacille Calmette-Guerin vaccination on C-peptide secretion in children newly diagnosed with IDDM. Diabetes Care 1998;21:1691-3.

131. Ristori G, Buzzi MG, Sabatini U, et al. Use of Bacille Calmette-Guerin (BCG) in multiple sclerosis. Neurology 1999;53:1588-9.

132. Vineis P, Miligi L, Crosignani P, et al. Delayed infection, family size and malignant lymphomas. J Epidemiol Community Health 2000;54:907-11.

133. Baris D, Zahm SH. Epidemiology of lymphomas. Curr Opin Oncol 2000;12:383-94.

Copyright © 2002 Massachusetts Medical Society.